IVIg vs placebo
Death · adults with renal vasculitis
Intravenous immunoglobulin showed no clear difference in death compared with placebo (low certainty).
1 finding from 1 review
- RR 0.2 [0.01, 3.88]1 study · 34 participantsLow
Findings
What do systematic reviews say?
80 questions · 86 findings · 10 reviews
No studies found 23 · 26.7%GRADE not reported 3 · 3.5%Very low 17 · 19.8%Low 19 · 22.1%Moderate 19 · 22.1%High 5 · 5.8%
IVIg vs placebo
Kidney function · adults with renal vasculitis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
IVIg vs placebo
Dialysis · adults with renal vasculitis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
IVIg vs placebo
Response at 3 months · adults with renal vasculitis
Intravenous immunoglobulin may leads to higher response at 3 months compared with placebo (low certainty).
1 finding from 1 review
- RR 2.33 [1.18, 4.61]1 study · 34 participantsLow
IVIg vs placebo
Relapse at 3 months · adults with renal vasculitis
Intravenous immunoglobulin showed no clear difference in relapse at 3 months compared with placebo (low certainty).
1 finding from 1 review
- RR 1.17 [0.39, 3.56]1 study · 34 participantsLow
IVIg vs placebo
Adverse events · adults with renal vasculitis
Intravenous immunoglobulin may leads to higher adverse events compared with placebo (low certainty).
1 finding from 1 review
- RR 31 study · 34 participantsLow
IVIg vs placebo
Serious infection · adults with renal vasculitis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
IVIg vs placebo
SAEs · NSTI
Intravenous immunoglobulin showed no clear difference in serious adverse events (SAE) compared with placebo (low certainty).
1 finding from 1 review
- Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes onlyRR 0.73 [0.32, 1.65]1 study · 100 participantsLow
IVIg vs placebo
Survival time · NSTI
1 finding from 1 review
- Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes onlyno estimate extracted1 study · 100 participantsLow
IVIg vs placebo
Assessment of long‐term morbidity · NSTI
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
IVIg vs placebo
All‐cause mortality · NSTI
Intravenous immunoglobulin showed no clear difference in mortality compared with placebo (low certainty).
1 finding from 1 review
- Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes onlyRR 1.17 [0.42, 3.23]1 study · 100 participantsLow
IVIg vs placebo
Muscle strength · people with inclusion body myositis
2 findings from 1 review
- no estimate extracted3 studies · 78 participantsGRADE not reported
- no estimate extractedStudies not reportedNo studies found
IVIg vs placebo
Change in muscle mass at 6 months (%) ‐ not measured · people with inclusion body myositis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
IVIg vs placebo
Change in handgrip strength at 6 months (%) ‐ not measured · people with inclusion body myositis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
IVIg vs placebo
Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured · people with inclusion body myositis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
IVIg vs placebo
Significant adverse events · people with inclusion body myositis
1 finding from 1 review
- no estimate extracted3 studies · 78 participantsGRADE not reported
Intravenous immunoglobulin plus phototherapy vs phototherapy alone
Use of ET (≥ 1); all studies · neonates with alloimmune hemolytic disease
It is very uncertain whether intravenous immunoglobulin plus phototherapy changes use of ET (≥ 1); all studies compared with phototherapy alone (very low certainty).
1 finding from 1 review
- RR 0.35 [0.25, 0.49]9 studies · 658 participantsVery low
Intravenous immunoglobulin plus phototherapy vs phototherapy alone
Use of ET (≥ 1); placebo‐controlled studies · neonates with alloimmune hemolytic disease
Intravenous immunoglobulin plus phototherapy showed no clear difference in use of ET (≥ 1); placebo‐controlled studies compared with phototherapy alone (moderate certainty).
1 finding from 1 review
- RR 0.98 [0.48, 1.98]2 studies · 172 participantsModerate
Intravenous immunoglobulin plus phototherapy vs phototherapy alone
ETs performed per infant; all studies · neonates with alloimmune hemolytic disease
1 finding from 1 review
- no estimate extracted9 studies · 658 participantsVery low
Intravenous immunoglobulin plus phototherapy vs phototherapy alone
ETs performed per infant; placebo‐controlled studies · neonates with alloimmune hemolytic disease
1 finding from 1 review
- no estimate extracted2 studies · 172 participantsModerate